PriceTargets.com logo

Aemetis - AMTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $12.95
  • Forecasted Upside: 377.86%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.71 As of 10/30/2024 03:52 PM ET
▼ -0.02 (-0.73%)

This chart shows the closing price for AMTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aemetis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMTX

Analyst Price Target is $12.95
▲ +377.86% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Aemetis in the last 3 months. The average price target is $12.95, with a high forecast of $28.00 and a low forecast of $3.50. The average price target represents a 377.86% upside from the last price of $2.71.

This chart shows the closing price for AMTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in Aemetis. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/3/2024Ascendiant Capital MarketsLower TargetBuy ➝ Buy$20.00 ➝ $19.00
8/19/2024UBS GroupLower TargetBuy ➝ Buy$8.25 ➝ $7.75
8/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
7/31/2024Truist FinancialReiterated RatingHold ➝ Hold$4.00 ➝ $3.50
5/13/2024Truist FinancialReiterated RatingHold ➝ Hold$3.50 ➝ $4.00
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
2/21/2024Stifel NicolausLower TargetBuy ➝ Buy$8.00 ➝ $6.50
1/23/2024Truist FinancialLower TargetHold ➝ Hold$5.00 ➝ $3.50
1/23/2024Stifel NicolausBoost TargetBuy ➝ Buy$7.50 ➝ $8.00
11/27/2023Stifel NicolausLower TargetBuy ➝ Buy$10.00 ➝ $7.50
9/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$28.00
8/22/2023Stifel NicolausBoost TargetBuy ➝ Buy$9.00 ➝ $10.50
8/16/2023UBS GroupUpgradeNeutral ➝ Buy$2.50 ➝ $10.50
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$28.00
7/7/2023Stifel NicolausBoost Target$9.00 ➝ $9.50
6/27/2023Stifel NicolausLower Target$9.80 ➝ $9.00
6/6/2023Piper SandlerBoost Target$2.00 ➝ $3.00
5/19/2023Stifel NicolausBoost Target$9.00 ➝ $9.80
4/27/2023Stifel NicolausLower Target$10.00 ➝ $9.00
4/14/2023Stifel NicolausLower TargetBuy$18.00 ➝ $10.00
4/13/2023Truist FinancialLower TargetHold$5.00 ➝ $2.50
2/27/2023Piper SandlerInitiated CoverageUnderweight$3.00
2/1/2023Truist FinancialLower TargetHold$9.00 ➝ $5.00
12/13/2022UBS GroupInitiated CoverageNeutral$4.25
11/16/2022Ascendiant Capital MarketsLower Target$26.00
11/4/2022Truist FinancialLower Target$9.00
8/9/2022Truist FinancialDowngradeBuy ➝ Hold$12.00
6/13/2022Credit Suisse GroupLower TargetOutperform$35.00 ➝ $27.00
6/6/2022Ascendiant Capital MarketsDowngradeOutperform$33.00
8/23/2021Stifel NicolausReiterated RatingBuy$31.00 ➝ $33.00
8/23/2021Credit Suisse GroupLower TargetOutperform$40.00 ➝ $31.00
8/16/2021HC WainwrightReiterated RatingBuy
7/14/2021Evercore ISIInitiated CoverageOutperform$25.00
3/22/2021Credit Suisse GroupInitiated CoverageOutperform$35.00
3/19/2021Ascendiant Capital MarketsReiterated RatingBuy
3/19/2021Truist FinancialInitiated CoverageBuy
3/15/2021HC WainwrightBoost Target$15.00 ➝ $28.00
3/8/2021Stifel NicolausInitiated CoverageBuy$25.00
12/3/2020HC WainwrightInitiated CoverageBuy$10.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/3/2024
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
8/31/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Aemetis logo
Aemetis, Inc. operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products. In addition, it produces and sells ethanol; and wet distillers grains, distillers corn oil, and condensed distillers solubles to dairies and feedlots as animal feed. Further, the company markets and supplies USP alcohol and hand sanitizer; and produces renewable natural gas, as well as distilled biodiesel from various vegetable oil and animal waste feedstocks. Additionally, it researches and develops conversion technologies using waste feedstocks to produce biofuels and biochemicals. Furthermore, it sells biodiesel primarily to government oil marketing companies. Aemetis, Inc. is headquartered in Cupertino, California.
Read More

Today's Range

Now: $2.71
Low: $2.68
High: $2.78

50 Day Range

MA: $2.57
Low: $2.21
High: $3.02

52 Week Range

Now: $2.71
Low: $2.10
High: $7.03

Volume

306,162 shs

Average Volume

789,738 shs

Market Capitalization

$120.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Aemetis?

The following sell-side analysts have issued stock ratings on Aemetis in the last year: Ascendiant Capital Markets, HC Wainwright, Stifel Nicolaus, StockNews.com, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for AMTX.

What is the current price target for Aemetis?

5 Wall Street analysts have set twelve-month price targets for Aemetis in the last year. Their average twelve-month price target is $12.95, suggesting a possible upside of 377.9%. HC Wainwright has the highest price target set, predicting AMTX will reach $28.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $3.50 for Aemetis in the next year.
View the latest price targets for AMTX.

What is the current consensus analyst rating for Aemetis?

Aemetis currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AMTX.

What other companies compete with Aemetis?

Other companies that are similar to Aemetis include Standard Lithium, Luxfer, ASP Isotopes, ARQ and Origin Materials. Learn More about companies similar to Aemetis.

How do I contact Aemetis' investor relations team?

Aemetis' physical mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The specialty chemicals company's listed phone number is (408) 213-0940 and its investor relations email address is [email protected]. The official website for Aemetis is www.aemetis.com. Learn More about contacing Aemetis investor relations.